TrialAnnals of surgery2018

Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.

Jin-Young Jang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.